• Pages: 701-706
• First Published: 25 March 2025

• Pages: 707-708
• First Published: 25 March 2025

• Pages: 709-710
• First Published: 25 March 2025

• Pages: 711-712
• First Published: 25 March 2025

• Pages: 713-714
• First Published: 25 March 2025

• Pages: 715-716
• First Published: 25 March 2025

• Pages: 717-718
• First Published: 25 March 2025

• Pages: 719-720
• First Published: 25 March 2025

• Pages: 721-722
• First Published: 25 March 2025

• Pages: 723-724
• First Published: 25 March 2025

• Pages: 725-729
• First Published: 25 March 2025

• Pages: 730-741
• First Published: 26 October 2024

Delphi Consensus on EGFRi-induced acneiform rash: management guidelines on early diagnosis and grading, prophylactic and pre-emptive treatment, reactive and personalized patient care.

• Pages: 742-758
• First Published: 02 December 2024

Genital herpes—guidelines for diagnostic and treatment (2024): strategies for diagnosis, management and follow-up of the most common sexually transmitted infection. The guidelines covers common clinical scenarios (including recurrent genital herpes), infection during pregnancy and coinfection with human immunodeficiency virus.

• Pages: 759-774
• First Published: 04 September 2024

ACNE AND ROSACEA

Open Access

oa

Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis

Aliyah King,  Marcus G. Tan,  Carly Kirshen,  Stanislav N. Tolkachjov, 

• Pages: 785-792
• First Published: 06 September 2024

This article relates to:

• Comment on ‘Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis’

  • Ankur Kapoor, 
  • Rachana Mehta, 
  • Muhammed Shabil, 
  • Sanjit Sah, 
  • Volume 39Issue 4Journal of the European Academy of Dermatology and Venereology
  • pages: e383-e384
  • First Published online: November 3, 2024

• Low-dose isotretinoin for difficult-to-treat rosacea: Enough evidence to be convinced—What's next?

  • Olivier Chosidow, 
  • Esther J. van Zuuren, 
  • Volume 39Issue 4Journal of the European Academy of Dermatology and Venereology
  • pages: 713-714
  • First Published online: March 25, 2025

Isotretinoin, a vitamin A derivative primarily known for treating acne vulgaris, has been investigated for rosacea despite its off-label use. This systematic review and meta-analysis of 16 studies involving 1445 patients examined low-dose isotretinoin (defined as ≤0.5 mg/kg/day) for the four main types of rosacea. This study found significant reduction in lesion count (p = 0.03) and erythema (p = 0.01), with low-dose isotretinoin outperforming topical retinoids and antimicrobials in reducing lesion count (p = 0.03). Its effect on erythema in rosacea however, did not meet statistical significant (p = 0.18). Improvements persisted 16 weeks post-treatment, with a relapse rate of 35% at 5.5 months. Study design heterogeneity limited comprehensive comparisons. Overall, low-dose isotretinoin appears to be an effective, well-tolerated, and safe treatment for rosacea.

• Abstract
• Full text
• PDF
• References
• Request permissions

Open Access

oa

Acne and the cutaneous microbiome: A systematic review of mechanisms and implications for treatments

Alicia Podwojniak,  Isabella J. Tan,  John Sauer,  Zachary Neubauer,  Hanna Rothenberg,  Hira Ghani,  Aarushi K. Parikh,  Bernard Cohen, 

• Pages: 793-805
• First Published: 13 September 2024

This article relates to:

• Will targeted microbiome modulation in the skin be the future of acne vulgaris treatment?

  • Kornélia Szabó, 
  • Lajos Kemény, 
  • Volume 39Issue 4Journal of the European Academy of Dermatology and Venereology
  • pages: 715-716
  • First Published online: March 25, 2025

Impact of Acne Therapies on the Skin Microbiome: This graphical abstract illustrates how various acne treatments affect the cutaneous microbiome, particularly focusing on Cutibacterium acnes and overall microbial diversity. Common treatments like doxycycline and benzoyl peroxide generally decrease C. acnes and reduce alpha diversity, while isotretinoin has variable effects. Newer therapies, including probiotics and plant extracts, are highlighted for their potential to restore microbial balance, suggesting a shift towards microbiome-focused treatment strategies.

• Abstract
• Full text
• PDF
• References
• Request permissions

PATIENT EXPERIENCE

Open Access

oa

A cross-sectional study on gender differences in body dysmorphic concerns in patients with skin conditions in relation to sociodemographic, clinical and psychological variables

F. Sampogna,  T. Samela,  D. Abeni,  C. Schut,  J. Kupfer,  A. P. Bewley,  A. Y. Finlay,  U. Gieler,  A. R. Thompson,  T. Gracia-Cazaña,  F. Balieva,  B. R. Ferreira,  G. B. Jemec,  L. Lien,  L. Misery,  S. E. Marron,  S. Ständer,  C. Zeidler,  C. Szabó,  J. C. Szepietowski,  A. Reich,  A. Svensson,  I. K. Altunay,  F. J. Legat,  V. Grivcheva-Panovska,  D. V. Romanov,  A. N. Lvov,  G. Titeca,  N. C. Vulink,  L. Tomás-Aragones,  S. van Beugen,  A. W. M. Evers,  F. J. Dalgard,  European Society for Dermatology and Psychiatry (ESDaP) Study collaborators , 

• Pages: 823-832
• First Published: 25 July 2024

• Abstract
• Full text
• PDF
• References
• Request permissions

Open Access

oa

Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome

P. L. Ortiz Romero,  Y. H. Kim,  K. Molloy,  P. Quaglino,  J. Scarisbrick,  S. Thornton,  K. Sandilands,  J. E. Dent,  A. Nixon,  A. Williams,  M. M. Shinohara, 

• Pages: 833-845
• First Published: 24 September 2024

This study found that all aspects of HRQL were compromised in patients with relapsed/refractory stage IB–IVB MF/SS. Different aspects of HRQL were worse in patients who were female, younger, Black/African American or who had worse mSWAT score, itch or performance status. Understanding of the individual's symptom burden, including patient-reported measures, should be used to inform treatment goals and therapeutic choice.

• Abstract
• Full text
• PDF
• References
• Request permissions

Open Access

oa

Psychometric properties of the revised internalized skin bias questionnaire

Melissa Butt,  Pritika Singh,  Amanda Keeler,  L. Claire Hollins,  Joslyn S. Kirby,  Vernon M. Chinchilli,  Andrea Rigby, 

• Pages: 846-854
• First Published: 09 October 2024

This article relates to:

• On the importance of assessing stigma in dermatological research

  • Fanny C. Kpenou, 
  • Khaled Ezzedine, 
  • Volume 39Issue 4Journal of the European Academy of Dermatology and Venereology
  • pages: 721-722
  • First Published online: March 25, 2025

This two-part study included consensus-building surveys and a cross-sectional survey among participants with self-reported dermatological conditions to assess instrument psychometric properties of the revised Internalized Skin Bias Questionnaire (ISBQ-R). Overall, 33 experts participated including 22 (66.7%) dermatologists or dermatology researchers and 11 (33.3%) patients. The revised survey was completed by 214 participants with various dermatological conditions. Adding and modifying new items (9 in total) resulted in an instrument with stronger internal consistency (Cronbach's alpha = 0.92) and a stronger correlation with other existing stigma measures (ρ = 0.72) as well as health-related quality of life (ρ = −0.68), anxious (ρ = 0.51) and depressive (0.53) symptoms. Additionally, the study further expanded upon previous research by exploring a two-factor structure, suggesting that the ISBQ-R could be used as a single or dual factor instrument depending on investigator goals.

• Abstract
• Full text
• PDF
• References
• Request permissions

SKIN CANCER

Open Access

oa

Histological deep margins in cutaneous squamous cell carcinoma of the scalp and risk of recurrence

Júlia Verdaguer-Faja,  Álvaro Guerra-Amor,  Carla Ferrándiz-Pulido,  Carlos Abril-Pérez,  Rafael Botella Estrada,  Emili Masferrer,  Daniel Lopez-Castillo,  Gustavo Deza,  Lorena Leal,  Ignasi Marti-Marti,  Verónica Ruiz-Salas,  Mireia Yébenes,  Laura Marqués Martin,  Carola Baliu,  Anna Castany,  Aram Boada,  Agustí Toll,  Ane Jaka, 

• Pages: 855-864
• First Published: 22 July 2024

Deep histological margins <1 mm do not confer a greater recurrence risk in scalp cSCC as long as the tumour is completely excised and the galea is not involved. However, peripheral margins <1 mm associate a higher risk of recurrence. Thus, surgical excision of cSCCs of the scalp should include the galea, which might act as an anatomical barrier.

• Abstract
• Full text
• PDF
• References
• Request permissions

no

BAUSSS biomarker improves melanoma survival risk assessment

Anthony J. Dixon,  Howard K. Steinman,  Alexander Nirenberg,  Christos C. Zouboulis,  Michael Sladden,  Catalin Popescu,  Stuart Anderson,  Caterina Longo,  J. Meirion Thomas, 

• Pages: 865-870
• First Published: 31 August 2024

This article relates to:

• Advancing biomarker-based prognostication in melanoma

  • Clio Dessinioti, 
  • Alexander J. Stratigos, 
  • Volume 39Issue 4Journal of the European Academy of Dermatology and Venereology
  • pages: 719-720
  • First Published online: March 25, 2025

The range of mortality risk within individual AJCC staging brackets is very wide. Administering adjuvant drug therapy based solely on AJCC T3b, T4a and T4b staging will result in many high-risk patients over 60 years of age being denied such drugs while other patients under young patients will be offered drug therapy despite having a relatively low risk primary tumour.

• Abstract
• Full text
• PDF
• References
• Request permissions

• Page: 871
• First Published: 25 March 2025

• Page: 872
• First Published: 25 March 2025

• Page: 873
• First Published: 25 March 2025

• Page: 874
• First Published: 25 March 2025

• Pages: e297-e299
• First Published: 08 August 2024

• Pages: e300-e302
• First Published: 09 August 2024

• Pages: e303-e305
• First Published: 09 August 2024

• Pages: e306-e309
• First Published: 13 August 2024

• Pages: e310-e312
• First Published: 13 August 2024

• Pages: e313-e316
• First Published: 16 August 2024

• Pages: e317-e319
• First Published: 21 August 2024

• Pages: e320-e322
• First Published: 21 August 2024

• Pages: e323-e325
• First Published: 21 August 2024

• Pages: e326-e328
• First Published: 22 August 2024

• Pages: e329-e332
• First Published: 27 August 2024

• Pages: e333-e335
• First Published: 10 September 2024

• Pages: e336-e341
• First Published: 10 September 2024

• Pages: e342-e343
• First Published: 11 September 2024

• Pages: e344-e346
• First Published: 12 September 2024

• Pages: e347-e349
• First Published: 12 September 2024

• Pages: e350-e352
• First Published: 13 September 2024

• Pages: e353-e355
• First Published: 13 September 2024

• Pages: e356-e358
• First Published: 13 September 2024

• Pages: e359-e362
• First Published: 16 September 2024

• Pages: e363-e365
• First Published: 16 September 2024

• Pages: e366-e368
• First Published: 16 September 2024

• Pages: e369-e371
• First Published: 18 September 2024

• Pages: e372-e374
• First Published: 20 September 2024

• Pages: e375-e377
• First Published: 25 September 2024

• Pages: e378-e380
• First Published: 17 October 2024

• Pages: e381-e382
• First Published: 08 November 2024

• Pages: e383-e384
• First Published: 03 November 2024